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Summary
Type I interferons (IFNs) inhibit viral replication and cell growth and enhance the immune
response, and therefore have many clinical applications. IFN-α2b ranks third in world market
use for a biopharmaceutical, behind only insulin and erythropoietin. The average annual
cost of IFN-α2b for the treatment of hepatitis C infection is $26 000, and is therefore
unavailable to the majority of patients in developing countries. Therefore, we expressed
IFN-α2b in tobacco chloroplasts, and transgenic lines were grown in the field after obtaining
United States Department of Agriculture Animal and Plant Health Inspection Service
(USDA-APHIS) approval. Stable, site-specific integration of transgenes into chloroplast
genomes and homoplasmy through several generations were confirmed. IFN-α2b levels
reached up to 20% of total soluble protein, or 3 mg per gram of leaf (fresh weight).
Transgenic IFN-α2b had similar in vitro biological activity to commercially produced
PEG-Intron™ when tested for its ability to protect cells against cytopathic viral replication
in the vesicular stomatitis virus cytopathic effect (VSV CPE) assay and to inhibit early-stage
human immunodeficiency virus (HIV) infection. The antitumour and immunomodulating
properties of IFN-α2b were also seen in vivo. Chloroplast-derived IFN-α2b increased the
expression of major histocompatibility complex class I (MHC I) on splenocytes and the total
number of natural killer (NK) cells. Finally, IFN-α2b purified from chloroplast transgenic lines
(cpIFN-α2b) protected mice from a highly metastatic tumour line. This demonstration of
high levels of expression of IFN-α2b, transgene containment and biological activity akin

Keywords: antitumour, antiviral, gene
containment, molecular ‘pharming’,
plant-made cytokine.

to that of commercial preparations of IFN-α2b facilitated the first field production of a
plant-derived human blood protein, a critical step towards human clinical trials and
commercialization.

Introduction
The type I interferons (IFNs) are part of the body’s first line of
defence against viral attack, and also invasion by bacterial
pathogens, parasites, tumour cells and allogeneic cells from
grafts (De Maeyer and De Maeyer-Guignard, 1988). IFN-α
and IFN-β display significant amino acid sequence homology
(30%) and bind to the same receptor (Pestka et al., 1987).
Members of the IFN-α family were the first to be highly
© 2007 The Authors
Journal compilation © 2007 Blackwell Publishing Ltd

purified, sequenced, cloned and produced by recombinant
DNA (Henco et al., 1985). Although they are known for their
inhibition of viral replication (Vilcek and Sen, 1996), IFN-α
is also involved in regulating cytokine and cytokine receptor
gene expression (Cousens et al., 1997), mediating cellular
proliferation and differentiation (Baron et al., 1992), modifying
immune cell distribution (Gresser et al., 1981; Ishikawa and
Biron, 1993) and activating natural killer (NK) cell cytotoxic
activity (Trinchieri, 1989). Indeed, IFN-α is a potent inhibitor
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of cell growth (Pestka et al., 1987). Perhaps most important,
IFN-α may be a critical link between the innate and adaptive
immune responses (Brassard et al., 2002).
Recombinant IFN-α2b was first approved by the Food and
Drug Administration (FDA) in 1986 for the treatment of hairy
cell leukaemia. Today, it is routinely administered for the
treatment of various cancers and viral diseases, but the cost
of treatment is prohibitive in many developing countries
(Stuart-Harris, 1997). The average cost of treatment using
the marketed recombinant IFN-α2b is $26 000 for a 12-month
course in the USA (Cowley, 2002).
The current therapeutic IFN-α2b is marketed under the
names PEG-Intron™ and Intron®A and is made in the microbial system Escherichia coli. Many eukaryotic proteins cannot
be expressed in prokaryotic hosts because the required
formation of two disulphide bonds (Bodo and Maurer-Fogy,
1986) presents a major limitation, adding to the cost of production of the mature, biologically active IFN-α2b. As a result,
IFN-α2b tends to aggregate to form inclusion bodies that
need to be solubilized, renatured and refolded into an active
protein (Swaminathan and Khanna, 1999). Other production
platforms, such as silkworm using baculovirus (Maeda et al.,
1985) or phage vectors (Slocombe et al., 1982), have been
used to express IFN-α2b at low levels that are not competitive
with the current system.
The plant nuclear genome has been used to express
human therapeutic proteins for more than a decade (Horn
et al., 2004). The expression of IFN-α2b and IFN-α8 has been
achieved by transforming potato nuclei (Ohya et al., 2001). In
tobacco, only 0.000017% fresh weight of transgenic leaves
contained IFN-β (Edelbaum et al., 1992). In addition, negligible
amounts of IFN-α were produced in nuclear-transformed
rice (Zhu et al., 2004). The low and variable expression levels
(caused by the position effect and gene silencing) using
nuclear transformation are less than adequate to be commercially feasible, in addition to the problems of transgene
containment that arise with field planting. Therefore,
strategies are required to increase expression levels in plants
and to facilitate transgene containment, allowing rapid and
less expensive production of therapeutic proteins.
The chloroplast expression system is quite versatile in
producing proteins as small as 20 amino acids, e.g. magainin
(DeGray et al., 2001), or as large as 135 kDa, e.g. Cry 1Ac
(McBride et al., 1995). Plastids can produce monomeric (Staub
et al., 2000; Fernandez-San Millan et al., 2003) or multimeric
proteins, including cholera toxin B (CTB) (Daniell et al., 2001),
CTB fusion proteins (Limaye et al., 2006), and Guy’s 13
(Daniell et al., 2004a) and herpes simplex virus (Mayfield et al.,
2003) antibodies. Therapeutic proteins with 2–17 disulphide

bonds, including human serum albumin (Fernandez-San
Millan et al., 2003) and somatotropin (Staub et al., 2000),
have already been produced in transgenic chloroplasts, with
appropriate post-translational modifications, including lipid
modifications, e.g. OspA lipoprotein (Glenz et al., 2006). The
chloroplast expression system has also been used to produce
fully functional vaccine antigens against bacterial pathogens,
including cholera (Daniell et al., 2001), anthrax (Watson
et al., 2004; Koya et al., 2005) and tetanus (Tregoning et al.,
2003), viral pathogens, including canine parvovirus (Molina
et al., 2004) and rotavirus VP6 (Birch-Machin et al., 2004),
and protozoan pathogens, including amoeba (Chebolu and
Daniell, 2006). The correct folding, disulphide bond formation and functionality of chloroplast-derived vaccine antigens
and therapeutic proteins have been demonstrated by several
assays, including macrophage lysis, GM1-ganglioside binding,
systemic immune responses, protection against pathogen
or toxin challenge and growth or inhibition of cell cultures
(Daniell et al., 2004a; Kamarajugadda and Daniell, 2006).
Multiple genes have been engineered via the chloroplast
genome in a single transformation event, facilitating the
synthesis and assembly of multicomponent vaccines (QuesadaVargas et al., 2005). Therefore, any therapeutic protein, irrespective of size, can be made with desired post-translational
modifications, with the notable exception of glycosylation
(Daniell et al., 2004a; 2005a). However, a few foreign proteins have been highly unstable within transgenic chloroplasts. For example, IFN-γ was degraded within chloroplasts
(< 0.2% TSP), but expression of up to 7% TSP was achieved
via fusion with β-glucuronidase (GUS) (Leelavathi and Reddy,
2003). Human insulin was similarly unstable in transgenic
chloroplasts; fusion with CTB resulted in high-level expression
(up to 16% TSP) and facilitated oral delivery studies to achieve
protection against the development of insulitis in non-obese
diabetic mice (Ruhlman et al., 2007). Such N-terminal degradation is not unique to chloroplasts. All commercially produced
insulin in bacteria or yeast is produced as a fusion protein;
when expressed without fusion, insulin is rapidly degraded.
Plant chloroplasts are ideal bioreactors, and it has been
shown that 1 acre of chloroplast transgenic plants can
produce up to 360 million doses of clean, safe and fully
functional anthrax vaccine antigen (Watson et al., 2004; Koya
et al., 2005). This is a relatively rapid system for scale-up,
because a single tobacco plant (a non-food, non-feed crop)
produces up to one million seeds, which is adequate to plant
more than 100 acres (8000 plants per acre and 40 metric
tons of leaf biomass per acre). Transgenes integrated into the
chloroplast genome are maternally inherited in most crops,
ensuring that they are not spread via pollen, and thereby
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offering transgene containment (Daniell et al., 1998; Daniell,
2002; Grevich and Daniell, 2005). Alternatively, cytoplasmic
male sterility can be engineered via the chloroplast genome,
thereby eliminating the production of viable pollen (Ruiz and
Daniell, 2005). An additional advantage is that transformed
seeds can be stored indefinitely and vaccine antigens can be
produced on demand, eliminating the need to stockpile
vaccine antigens under low temperature and with limited
shelf life.
In this study, we investigate the expression of IFN-α2b in
transgenic tobacco chloroplasts (cpIFN-α2b), and evaluate
the functionality of purified IFN-α2b using commercial IFNs as
comparative standards.

Results and discussion
The 5.9-kb universal chloroplast vector (Daniell et al., 2005b)
used in this study contains several unique features that
facilitate the integration of cloned DNA into the plastid
genome. This process occurs exclusively through site-specific
homologous recombination, thereby excluding the foreign
vector DNA and enhancing transgene expression. The pLDCtV vector incorporates the trnA and trnI genes (chloroplast
transfer RNA transcripts coding for alanine and isoleucine,
respectively) from the inverted repeat region of the tobacco
chloroplast genome as flanking sequences for homologous
recombination (Daniell et al., 2005b). This vector was successfully used as the backbone for insertion of the expression
cassette 5′UTR/HIS/THR/ IFNα2b (Figure 1a).

Selection and regeneration of transgenic lines
From seven bombarded Petit Havana leaves, 27 green shoots
appeared after 4 weeks. From eight bombarded LAMD-609
leaves, 12 green shoots appeared within 7 weeks, indicating
that the shoots from the low-nicotine tobacco LAMD-609
took longer to sprout and were less numerous. Untransformed cells appeared bleached on the antibiotic because
they did not contain the aadA gene. For the second round of
selection, the Petit Havana shoots were able to thrive on
500 µg/mL spectinomycin, whereas the LAMD-609 transformants only grew when the antibiotic concentration was
decreased to 350 µg/mL spectinomycin.

Confirmation of homoplasmy
For both tobacco varieties, Southern blots were performed
to confirm integration of the IFN α2b cassette using
appropriate DNA probes. A 0.81-kb DNA fragment containing

the chloroplast trnI and trnA flanking sequences was used
to probe total leaf DNA to determine homoplasmy or
heteroplasmy after bombardment with pLD-RF-IFNα2b
(Figure 1a). This determination was also used to estimate
the chloroplast genome copy number. BamHI-digested
DNA from transformed plants produced a 9.9-kb fragment
when probed (Figure 1b). Untransformed plant DNA from
both tobacco varieties produced a single 7.9-kb fragment,
indicating no integration of foreign DNA. All but one transgenic line exhibited only the 9.9-kb fragment (Figure 1b),
indicating homoplasmy; plant #3c showed both the 7.9- and
9.9-kb fragments, indicating heteroplasmy. The attainment
of homoplasmy in transformants provides a potential integrated transgene copy number of 10 000 copies per tobacco
leaf cell (100 chloroplasts per plant cell × 100 genomes per
chloroplast), and indicates that homoplasmy can be achieved
in the T0 generation. Transgene integration and maintenance
of homoplasmy were demonstrated in subsequent generations
(T1, T2, T3, etc.; data not shown).

Characterization of cpIFN-α2b
IFN-α2b is functional in its monomeric form, but has a tendency
to aggregate (Wang, 1999). For LAMD-609, monomers of
cpIFN-α2b protein were detected at approximately 21.5 kDa
(Figure 1c), as a result of the presence of the polyhistidine
tag and thrombin cleavage site, and smaller than the PEGIntron™ standard (approximately 32 kDa). For Petit Havana,
monomers of cpIFN-α2b protein were also detected at
approximately 21.5 kDa (Figure 1d), slightly larger than the
size of the Intron®A standard (19.2 kDa). In addition, dimers
and multimers of cpIFN-α2b were observed in both LAMD609 and Petit Havana.
The physical condition of the plants, its age and external
factors, such as illumination and changes in temperature in the
growth chamber and glasshouse, all contribute to the levels
of protein expressed. Using enzyme-linked immunosorbent
assay (ELISA), we examined the variation in cpIFN-α2b levels
in young, mature and old leaves of the same transgenic
plants of Petit Havana and LAMD, as well as under different
durations of illumination, employing PEG-Intron™ and
recombinant human IFN-α2b (rHu-IFN-α2b) as standards. In
all transgenic lines grown in the glasshouse, higher levels of
cpIFN-α2b expression were obtained when rHu-IFN-α2b
was used as the standard (Figure 2). Old leaves showed
the lowest levels of expression, corresponding to senescence
inducing high proteolytic activity. Both young and
mature leaves showed high levels of IFN-α2b expression,
ranging from 1 to 3 mg/g fresh weight, or 8%–21% TSP, in
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Figure 1 Confirmation of chloroplast integration and determination of homoplasmy/heteroplasmy in the T0 generation of both varieties. (a) The 0.81kb DNA probe containing chloroplast flanking sequences. (b) DNA fragments of 7.9 kb indicate untransformed chloroplasts and DNA fragments of 9.9 kb
are observed when the chloroplast genome contains the integrated transgenes. Lanes 1, 5, untransformed wild-type; lanes 2–4, transgenic LAMD-609
lines; lanes 6–9, transgenic Petit Havana lines. (c) Western blot of LAMD-609 transgenic plants expressing chloroplast-derived interferon-α2b (cpIFNα2b). Low-nicotine tissue extract separated by 15% sodium dodecylsulphate-polyacrylamide gel electrophoresis (SDS-PAGE), with cpIFN-α2b detected
by mouse monoclonal antibody against human IFN-α. Lane 1, 80 ng PEG-Intron™ standard; lane 2, protein marker; lane 3, wild-type (untransformed)
LAMD-609; lanes 4–7, transgenic LAMD-609 lines expressing monomers and multimers of cpIFN-α2b. (d) Western blot of Petit Havana transgenic plants
expressing cpIFN-α2b. Petit Havana leaf extract separated by 15% SDS-PAGE, with cpIFN-α2b detected by mouse monoclonal antibody against human
IFN-α. Lane 1, 38 ng of Intron®A; lane 2, protein marker; lane 3, 190 ng of Intron®A; lane 4, wild-type (untransformed) Petit Havana; lanes 5–7,
transgenic Petit Havana lines expressing monomers and multimers of cpIFN-α2b; lanes 8, 9, Escherichia coli-transformed with IFN-α2b.

T1 LAMD transgenic lines (Figure 2a,b). In Petit Havana transgenic lines, IFN-α2b expression ranged from 0.2 to 1.2 mg/g
fresh weight, or 2%–14% TSP (Figure 2c,d). The variation in
expression levels may be the result of a decrease in cpIFN-α2b
levels on continuous illumination in Petit Havana transgenic
lines; in LAMD transgenic lines, such illumination increased
IFN-α2b accumulation. This highlights the difference
between Petit Havana and LAMD in the toleration of continuous light. The differences in protein levels correlate
with differences in light intensity, as the same source of
nutrition was provided to all transgenic lines. It is also known
that 5′ untranslated regions of the psbA gene, located
upstream of the IFNα2b cassette, enhance the translation of
the psbA gene in light (Eibl et al., 1999). The dramatic differ-

ence in IFN-α2b levels in glasshouse-grown LAMD plants is
most probably a result of light-regulated translational
enhancement by the psbA regulatory sequences.

Expression of cpIFN-α2b in field-grown biomass
In addition to the glasshouse, plants grown in the field were
also examined. Approximately 2.5 months after transplantation in October, the biomass on stalks was cut 15 cm
above ground with a forage harvester (Hege, Eging am See,
Germany). From a single harvest, 107.7 kg of biomass was
collected, shipped and stored in a commercial freezer (–20 °C)
prior to analysis and purification. The plants had an average
height of 43.2 cm and weighed 64 g. A single acre of
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Figure 2 Quantitation of interferon-α2b purified from chloroplast transgenic lines (cpIFN-α2b). Crude extracts of transgenic leaf material were analysed
for IFN-α2b expression by indirect enzyme-linked immunosorbent assay (ELISA). Quantitation of transgenic IFN-α2b was performed on the T1 generations
of LAMD (a, b) and Petit Havana (c, d) plants. (a, c) Quantitation of cpIFN-α2b as a percentage of total soluble protein (TSP). (c, d) Quantitation of
cpIFN-α2b as milligrams of transgenic protein per gram fresh leaf weight. Two different standards were used in the ELISA: recombinant IFN-α2b with a
covalent conjugate of monomethoxy polyethylene glycol (PEG-Intron™) and recombinant human IFN-α2b (rHuIFN-α2b). Y, young leaves (top few in the
plant); M, mature leaves (fully developed); O, old leaves (bottom senescent leaves with decreased pigments). Duration of illumination: 0, 1, 3 and 5 days
of continuous illumination. Error bars represent the standard error of the mean.

tobacco biomass can be harvested four to six times within a
growing season. As a result, there is the potential to generate
greater than 1 metric ton of fresh biomass per acre under
these conditions. As expected, Petit Havana plants had less
height and weight per plant, and therefore less biomass per
acre than commercial cultivars, which can generate up to 40
times more per acre (Cramer et al., 1999). Based on 0.8 mg
IFN-α2b per gram of leaf biomass, 107.7 kg of harvested
biomass contained about 87.2 g of IFN-α2b. The limited yield
was the result of a single harvest of biomass at a very early age
because of premature flowering of Petit Havana in the field.
Lower expression of IFN-α2b was anticipated in young leaves
because the psbA regulatory sequence used to express IFNα2b is developmentally regulated, and optimal levels of expression are achieved only in mature leaves of fully grown plants
(Fernandez-San Millan et al., 2003; Daniell et al., 2004a;
Watson et al., 2004; Koya et al., 2005; Limaye et al., 2006).

We were able to generate 137.13 mg of IFN-α2b from
100 g of biomass at maturity in the glasshouse (Table 1). On
the basis of observed expression levels, this should yield
5.5 × 107 mg of IFN-α2b in 1 acre of tobacco plants. A
weekly dose of PEG-Intron™ (Schering Corporation, Kenilworth, NJ, USA), the E. coli-produced recombinant IFN-α2b
treatment for hepatitis C, is 70 µg for an average 70-kg
male. Based on a purification efficiency of 50%, approximately
400 million weekly doses for the treatment of hepatitis C can
be produced in just 1 acre.

Functional evaluation of cpIFN-α2b using vesicular
stomatitis virus (VSV)
cpIFN-α2b activity was first evaluated by its antiviral properties.
The activity of IFN-α2b is typically assayed by measuring its
ability to inhibit the in vitro replication of VSV (Rubinstein
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Table 1 Yield of interferon-α2b purified from chloroplast transgenic lines (cpIFN-α2b) in LAMD transgenic lines grown in the glasshouse
Leaves

IFN-α2b

Average weight

IFN-α2b in fresh leaf

IFN-α2b per age group (mg)

Leaf age

per plant

per leaf (mg)

per leaf (g)

(mg/g)

(no. leaves × [IFN-α2b] per leaf)

Young

3.20

3.50

2.50

1.40

11.20

Mature

7.80

16.00

8.00

2.00

124.80

Old

4.50

0.25

5.00

0.05

Total amount of recombinant IFN-α2b per plant

1.13
137.13

Young leaves, top 2–3 leaves; old leaves, bottom 2–3 senescent leaves; mature leaves, selected from the middle of the plant. cpIFN-α2b levels were quantified
by enzyme-linked immunosorbent assay (ELISA).

et al., 1981). Staining cells with crystal violet at the end of
the assay enabled us to visualize the degree of cytopathicity
under the microscope. Representative photographs are shown
in Figure 3a. The mock controls (VSV alone and medium
alone) were assigned protection values of 0% (complete
cytopathicity) and 100% (complete protection), respectively.
To rule out any toxic effects, IFN-α2b was tested in the
absence of virus. As can be seen by the example of PEGIntron™, cells grew normally in the presence of up to tenfold
higher concentrations of IFN-α2b (Figure 3a). All experimental
preparations of cpIFN-α2b protected cells, and did so in a
dose-dependent manner. Purified cpIFN-α2b protected cells
even when diluted 500-fold (data not shown). A crude
extract of transgenic leaf material was still protective at the
1000-fold dilution (Figure 3a). Crude extracts of non-transgenic
tobacco leaves were not protective, at any dilution, indicating
that it is the presence of transgenic IFN-α2b in the plant that
mediates the protection.
Crystal violet staining also enabled us to quantify the
biological activity of the various IFN-α2b preparations tested.
The activity is expressed in international units (IUs) and was
calculated by comparing the levels of protection with controls. cpIFN-α2b from both laboratory and field sources
was strongly protective (Table 2), as were the corresponding
crude extracts. The weekly dose of PEG-Intron™ is also
depicted in the table, to illustrate the levels of activity achievable
via the transgenic chloroplast system. As can be seen,
100 mg of transgenic leaf material expressing IFN-α2b has
approximately the same biological activity as one weekly dose
of PEG-Intron™.

Functional evaluation of cpIFN-α2b using human
immunodeficiency virus (HIV)
To further investigate the antiviral properties of cpIFN-α2b,
we assessed the protection of cells from HIV-1 entry and

Table 2 Biological activity of interferon-α2b (IFN-α2b) preparations
Sample

Concentration (IU/mL)*

Purified cpIFN-α2b (laboratory sample)

7.7 × 107

Purified cpIFN-α2b (field sample)

1.3 × 108

cpIFN-α2b crude extract (laboratory sample)

1.3 × 106

cpIFN-α2b crude extract (field sample)

2.8 × 106

Wild-type crude extract

4.5 × 100

PEG-Intron™ (maximum weekly dose)†

1.1 × 106

Baby hamster kidney (BHK) cells were pretreated with the indicated samples
for 24 h prior to vesicular stomatitis virus (VSV) exposure. Concentrations
were determined by comparing the results of each experimental condition
with the performance of PEG-Intron™, the positive control. These data
represent the mean of four independent experiments, with each treatment
performed in duplicate.
*IU: International units, calculated by comparison with a leucocyte reference
standard obtained from the National Institute of Allergy and Infectious
Diseases (NAID) Repository.
†The maximum weekly dose is based on the manufacturer’s specified dosage
and is calculated for a 70-kg individual.

integration. The targets for infection in this assay are TZM-BL
cells, a derivative of HeLa cells that express CD4, CCR5 and
CXCR4, rendering them excellent targets for infection by
both tropic varieties of HIV. These cells also contain a luciferase
expression cassette that is driven by the HIV long terminal
repeat (LTR). Thus, when HIV productively infects TZM-BL, the
high levels of Tat produced drive transcription by the endogenous LTR, resulting in quantifiable luciferase expression.
Two different HIV isolates were tested: the CCR5-tropic
strain BaL and the CXCR4-tropic strain IIIB. PEG-Intron™
demonstrated approximately 80% inhibition of luciferase
activity at both dilutions tested (Figure 3b,c). cpIFN-α2b from
laboratory-derived plants showed nearly 100% protection
from infection by both HIV strains at the 10-fold dilution; at
the 100-fold dilution, protection from HIV BaL was nearly 60%
(Figure 3b) and, from HIV IIIB, better than 80% (Figure 3c).
cpIFN-α2b from field-derived plants also demonstrated
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Figure 3 Transgenic tobacco plants produce interferon-α2b (IFN-α2b) with biological activity in vitro. (a) Transgenic IFN-α2b inhibits vesicular stomatitis
virus (VSV)-induced cytopathicity. Baby hamster kidney (BHK) cells were pretreated with the indicated samples for 24 h prior to VSV exposure. At the
conclusion of the assay, the cells were washed and stained with crystal violet for microscopic examination. (b, c) Transgenic IFN-α2b inhibits human
immunodeficiency virus (HIV) infection, as determined by a decrease in luciferase expression. TZM-BL cells were pretreated for 24 h with the indicated
reagents, and then exposed to two different HIV isolates: the CCR5-tropic strain BaL (b) and the CXCR4-tropic strain IIIB (c). All treatments were
performed in triplicate. Error bars represent the standard error of the mean. Asterisks indicate P < 0.05.

strong protection: better than 65% for both dilutions and
both strains tested.
Protection by transgenic plant crude extract was also noted.
For HIV BaL, better than 50% protection was observed
and, for HIV IIIB, better than 67% protection. Wild-type
crude extract did not protect cells at all from infection by HIV
BaL, but did provide minimal protection (< 20%) from HIV
IIIB, indicating that it is the IFN-α2b expressed by transgenic
leaves that provides the bulk of specific protection.
In summary, both forms of cpIFN-α2b tested (purified
and crude extract, from both laboratory and field sources)
were protective in in vitro antiviral assays. The successful
performance of the transgenic plant crude extracts in the
in vitro assays, with strong biological activity of cpIFN-α2b,

demonstrates the advantage of the higher levels of expression
observed in chloroplast transgenic lines. After performing
initial in vitro studies using plant crude extracts, all subsequent
investigations were conducted with purified cpIFN-α2b;
the results observed were very similar to those of currently
available commercial sources of IFN.

In vivo studies
Amongst the myriad effects imparted by IFN-α2b, the upregulation of major histocompatibility complex class I (MHC I)
molecules (de Waard-Siebinga et al., 1995) and the activation
of NK cells (Gidlund et al., 1978; Senik et al., 1979) comprise
a major part of its antiviral and antitumour properties. Our
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Figure 4 Immunohistochemical detection of the interferon response in mouse spleens. (a) Representative photographs of mouse spleen tissue. The
tissues were fixed and 10-µm sections were stained for either the natural killer (NK) cell markers CD49b and NK1.1 or major histocompatibility complex
class I (MHC I). For NK cell marker staining, the channels were read individually and also overlaid. It should be noted that, because of the natural expression
profile of MHC I, all cells are presumed to be positive. Therefore, these data are designed to evaluate relative differences between the conditions. Isotype
controls depict the background fluorescence of the native tissue. Photographs were taken with a 20× objective and are representative of more than 100
sections of each treatment condition. (b, c) Analysis of the mean fluorescence intensity (MFI) of splenocytes stained for MHC I-positive cells (b) and NK
cells (c). All tissue samples were acquired with equivalent MFI. Error bars in (b) and (c) represent the standard error of the mean. Asterisks indicate
statistical comparisons between PEG-Intron™ and phosphate-buffered saline (PBS), and interferon-α2b purified from chloroplast transgenic lines
(cpIFN-α2b) and PBS, with significant P values of less than 0.05.

in vivo assays were designed to address whether our preparations of cpIFN-α2b were similarly capable of regulating
the immune response.
cpIFN-α2b up-regulates MHC I expression on splenocytes
Blind screens of more than 100 sections of spleen tissue from
each treatment condition were performed for the expression of cell surface markers. Initially, the expression of MHC I
on splenocytes was analysed. Because all nucleated cells
express MHC I antigens, we were interested in the relative
differences between the treatment groups. The basal level

of MHC I expression of mouse spleen tissue can be seen in
the phosphate-buffered saline (PBS) treatment condition
(Figure 4a). Treatment with cpIFN-α2b increased MHC I
expression to levels similar to those achieved by PEG-Intron™
treatment. These results were confirmed by quantifying the
immunofluorescence emission data. Spleen tissue isolated
from PBS-treated mice demonstrated a mean fluorescence
intensity (MFI) of MHC I expression of 74.7 units (Figure 4b).
Mice treated with PEG-Intron™ had a significantly higher MFI
(88.02 units; P = 0.04). Mice treated with cpIFN-α2b also had
a significantly higher MFI (83.27 units; P = 0.003).
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Figure 5 Phenotypic analysis of splenocytes. Total splenocytes isolated from the various groups of mice in this study were analysed by flow cytometry
for surface marker expression. (a) Representative flow cytometry plots showing splenocyte expression of major histocompatibility complex class I (MHC I)
and CD49b. Quadrant positions are based on isotype controls. (b) Comparison of the mean fluorescence intensity (MFI) of MHC I across the various
treatment groups. All cells comprising the MHC I-positive population (i.e. both CD49b-positive and CD49b-negative populations) are represented.
(c) Comparison of the expression of natural killer (NK) cell markers (CD49b and NK1.1) across the various treatment groups. The data in (b) and
(c) represent the means of each treatment group. Error bars represent the standard error of the mean. Asterisks indicate statistical comparisons between
PEG-Intron™ and phosphate-buffered saline (PBS), and interferon-α2b purified from chloroplast transgenic lines (cpIFN-α2b) and PBS, with significant
P values of less than 0.05.

cpIFN-α2b increases the number of NK cells in vivo
Spleen tissue was also screened for the presence of NK cells.
In PBS-treated mice, little staining of cells positive for the NK
cell markers CD49b and NK1.1 was found (Figure 4a). By
contrast, more positive NK cell staining was detected in mice
treated with cpIFN-α2b. When the fluorescence emissions of
the overlaid images were quantified, spleen tissue isolated
from mice treated with PBS demonstrated a combined MFI
(MFICD49b × MFINK1.1) of 3797 units (Figure 4c). Mice treated
with PEG-Intron™ showed a significantly higher combined
MFI of 9366 units (P = 1.6 × 10–9). Mice treated with cpIFNα2b also showed a significantly higher combined MFI of
8284 units (P = 8.9 × 10–15).
Finally, the splenocytes were analysed by flow cytometry.
Representative plots are depicted in Figure 5a. Splenocytes
isolated from mice treated with either PEG-Intron™ or cpIFNα2b stained nearly 90% positive for MHC I expression (data
not shown), and more than 6% were positive for the
expression of the NK cell marker CD49b (Figure 5c). Mice
treated with PBS showed significantly fewer splenocytes
staining positive for CD49b (P = 0.04). By contrast, mice
treated with cpIFN-α2b showed nearly 5.5% of splenocytes

staining positive for CD49b, also a significant difference
(P = 1.3 × 10–5). In addition, the MHC I-positive cell population
from mice treated with cpIFN-α2b preparations showed a
nearly 20% greater MFI than that of PBS-treated mice
(Figure 5b), a significant difference (PEG-Intron™, P = 0.01;
cpIFN-α2b, P = 0.03).
Taken together, these data lend support to the concept that
cpIFN-α2b possesses the biological function of up-regulating
MHC I expression and NK cell markers.
cpIFN-α2b inhibits tumour metastasis in vivo
IFN-α has well-characterized antitumour activity in malignancies
(Gutterman, 1994; Belardelli et al., 1998). The antitumour
properties of cpIFN-α2b were assessed against B16-F10 cells,
an aggressive metastatic melanoma cell line (Fidler et al., 1976).
The degree of tumour metastasis could be determined
empirically by macroscopic observation of the lungs after
sacrifice (Figure 6a). Mice treated with PBS showed the
highest degree of metastasis, indicated by near-complete
coverage of the lung with tumour. By contrast, mice treated
with either PEG-Intron™ or cpIFN-α2b exhibited quantifiably
fewer black spots (Figure 6a).
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Figure 6 Transgenic tobacco plants produce interferon-α2b (IFN-α2b) with biological activity in vivo. (a) Photographs of lungs of mice injected with the
metastatic tumour B16-F10. Mice were treated via intraperitoneal injection, as indicated, for three consecutive days. (b) Mean colour intensity of tumour
metastases. Photographs of lung samples were analysed for colour intensity. All samples were photographed with equal exposure settings. A calculation
of total colour was then achieved by selecting only those pixels that corresponded to the lung tissue. The mean colour intensity was calculated for all
samples of a particular group. The lower the intensity, the greater amount of black (tumour) in the image. Error bars represent the standard error of the
mean. Asterisks indicate statistical comparisons between PEG-Intron™ and phosphate-buffered saline (PBS), and purified cpIFN-α2b and PBS, with
significant P values of less than 0.05.

These data were analysed further by calculating the colour
intensity of the images, designed to help quantify the relative
intensity of tumour (black) on a background of healthy lung
tissue (red/pink). The calculations are summarized in
Figure 6b, in which the mean colour intensity (MCI) of each
group is plotted. As expected, mice treated with the positive
control preparation (PEG-Intron™) had a mean MCI of
40.82 units, significantly higher than that of the animals
treated with PBS (21.58 units; P = 0.02). cpIFN-α2b also
significantly reduced the tumour metastasis to a mean MCI
of 34.24 units (P = 1.1 × 10–7). These data suggest that the
treatment of mice with cpIFN-α2b mediates antitumour
activity and helps protect mice from the metastatic effects of
the B16-F10 tumour line. Once again, as in previous assays,
the performance of cpIFN-α2b is comparable with that of its
commercial counterpart.
In conclusion, we have expressed IFN-α2b in tobacco chloroplasts, and transgenic lines were grown in the field after
obtaining United States Department of Agriculture Animal
and Plant Health Inspection Service (USDA-APHIS) approval.
Southern blots confirmed the stable, site-specific integration
of transgenes into chloroplast genomes and homoplasmy in
several generations. Western blots detected monomeric and
multimeric forms of cpIFN-α2b. ELISA showed up to 20% of
TSP, or 3 mg IFN per gram of leaf (fresh weight). cpIFN-α2b

possesses both in vitro and in vivo biological activity in both
crude extract and purified forms. The induced up-regulation
of MHC I molecules and activation of NK cells are consistent
with the critical role played by IFN-α2b in early immune
responses. MHC I is a necessary component of the antiviral
response, increasing the presentation of foreign peptides to
circulating immune cells primed for attack. NK cells survey the
body for changes in MHC I expression, an indicator of abnormal
situations, such as cancer. The priming of NK cells mediated
by IFN-α2b helps to mobilize the immune system and facilitate
the clearance of tumours. Our results provide a simple and costeffective method for the production of functional IFN-α2b.
The commercial potential of molecular ‘pharming’ of
plant-made pharmaceuticals has resulted in regulatory agencies formulating guidelines to protect the environment and
consumers. Clearly, the rationale and risks of molecular
pharming are very different from those of the first generation
of crops genetically modified to enhance agronomic traits. In
this study, we have used chloroplast genetic engineering to
minimize the transmission of transgenes via pollen. We have
also used a non-food/non-feed crop and expressed the
therapeutic protein only in vegetative tissues. In addition, the
transgenic plants were harvested before any reproductive
structures appeared, thereby eliminating the spread of
transgenes via pollen or seeds. This is the first example of a
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human blood protein produced in the field in transgenic
plants. Large-scale production and purification in Good
Manufacturing Practice (GMP) facilities should lead to human
clinical trials and further advances in this field.

fragment (Figure 1a). The probe was prepared by random primed
P-labelling (Ready-To-Go DNA labelling beads; Amersham Biosciences,
Pittsburgh, PA, USA). The probes were hybridized to the membrane
using the Quick-hyb solution and protocol (Stratagene, La Jolla, CA,
USA), as described previously (Kumar and Daniell, 2004; Daniell
et al., 2005b). The radiolabelled blots were exposed to X-ray films
and then developed in the X-ray film processor.
32

Experimental procedures
Immunoblot analysis
Construction of the pLD-RF-IFNα2b vector
The IFNα2b gene was purchased from the American Type Culture
Collection (Gwynne et al., 1993) (ATCC #53371; Manassas, VA,
USA) in E. coli strain JM83 K-12. Sequencing results confirmed that
the fragment in the pGL2BIFN vector was IFNα2b. Two overlapping
primers were used at the 5′ end of the IFNα2b gene to include a
thrombin cleavage site and a polyhistidine tag, with the reverse
primer containing a NotI restriction site for further subcloning. After
confirmation of the DNA sequence, the gel-eluted polymerase chain
reaction (PCR) product was ligated into a Bluescript vector containing
the 5′ untranslated region (UTR) of the psbA gene. This fragment
(5′UTR/HIS/THR/IFNα2b) was inserted into the universal chloroplast
vector pLD to create pLD-RF-IFNα2b. The recombinant DNA techniques were carried out as detailed previously (Sambrook et al., 1989).

Plant extraction buffer (PEB) was made fresh on the same day as
the Western analysis, and contained 100 mM NaCl, 10 mM ethylenediaminetetraacetic acid (EDTA) (pH 8), 200 mM Tris-HCl (pH 8),
0.05% Tween-20, 0.1% sodium dodecylsulphate (SDS), 14 mM βmercaptoethanol (BME), 400 mM sucrose and 2 mM phenyl methyl
sulphonyl fluoride (PMSF), which specifically inhibits serine proteases,
such as chymotrypsin, trypsin and thrombin. From each transgenic
Petit Havana and LAMD-609 line, leaf sections were cut and labelled
as old (bottom), mature (middle) and young (top) leaves. Leaf
material (100 mg) was ground in liquid nitrogen in cold, autoclaved
mortars and pestles. PEB (200 µL) was added to each plant sample on
ice and then vortexed for 10 s. A mouse antihuman IFN-α antibody
(Abcam, Cambridge, MA, USA) was used for the immunoblot analysis
of the extracted plant proteins.

Bombardment and selection of transgenic shoots

ELISA

The Bio-Rad PDS-1000/He biolistic device (Bio-Rad, Hercules, CA,
USA), a particle delivery system, was used to bombard tobacco
leaves (Kumar and Daniell, 2004; Daniell et al., 2005b). Two varieties
of tobacco (Nicotiana tabacum) were generated for the bombardment: Petit Havana and LAMD-609 (low-nicotine hybrid produced by
backcrossing a Maryland type variety, MD-609, with a low-nicotineproducing burley variety, LA Burley 21) (Collins et al., 1974). After
recovering in the dark for 48 h, leaves were cut under the hood into
5-mm2 pieces and placed on regeneration medium of plants (RMOP)
plates containing 500 µg/mL of spectinomycin for the first round
of selection for transformants (Daniell, 1997; Daniell et al., 2005b).
Approximately 4 weeks later, the shoots were cut into 2-mm2 pieces
and transferred to fresh RMOP plates containing spectinomycin for a
second round of selection. During this round of selection, the shoots
that appeared were tested for cassette integration into the chloroplast genome by PCR analysis. Finally, after 4 weeks of secondary
selection, the shoots were transferred to sterile jars containing fresh
Murashige and Skoog medium without hormones (MS0) medium
with 500 µg/mL spectinomycin (Kumar and Daniell, 2004; Daniell
et al., 2005b). When the shoots grew to fill the jars, the transgenic
lines were transferred to pots with soil containing no antibiotic.
Potted plants were grown in a 16-h light/8-h dark photoperiod in the
growth chamber at 26 °C or in the glasshouse or field.

Plant tissues were ground in liquid nitrogen using sterile mortar
and pestles, and then placed on ice. Plant protein extraction buffer
(500 µL of 15 mM Na2CO3, 35 mM NaHCO3, 3 mM NaN3, 0.1%
Tween-20, pH 9.6) was added to each sample and vortexed briefly.
The samples were centrifuged at 4000 × g for 2 min and then
placed back on ice. The supernatant was passed through a 0.22-µm
filter and transferred to a fresh tube. Dilutions of crude extract
ranging from 1 : 5 to 1 : 5000 were made in coating buffer (15 mM
Na2CO3, 35 mM NaHCO3, 3 mM NaN3, pH 9.6). PEG-Intron™ (a
covalent conjugate of recombinant IFN-α2b with monomethoxy
polyethylene glycol; Schering Corporation) was used as the standard
and was also diluted in coating buffer. Aliquots of 100 µL of the
diluted plant protein extract and standards were pipetted into a
96-well microtitre enzyme immunoassay (EIA) plate in duplicate. The
plate was covered with parafilm and incubated at room temperature
for 4 h. The wells were washed three times with 0.1% Tween-20 in
phosphate-buffered saline (PBS-T), followed by three washes with
deionized water. The plate was patted dry on paper towels, without
letting the wells go completely dry. To detect the presence of IFNα2b in each sample, 100 µL of mouse monoclonal antibody against
human IFN (clone MMHA-2, PBL Biomedical, Piscataway, NJ, USA),
diluted 1 : 2500 in PBS supplemented with 3% non-fat, powdered
milk (Carnation) and 0.1% Tween-20 (P-T-M), was added to each
well and incubated for 1 h at 37 °C. After incubation, the wells were
washed as above, and 100 µL of the secondary antibody (goat antimouse immunoglobulin G) conjugated to horseradish peroxidase
(American Qualex, San Clemente, CA, USA), diluted 1 : 5000 in P-T-M,
was added to the wells and incubated for 1 h at 37 °C. After incubation, the wells were washed as above, and 100 µL of 3,3′,5,5′tetramethylbenzidine (TMB) substrate (American Qualex) was
added to the wells. After allowing 5 min for colour change, 100 µL
of 2 M sulphuric acid was added to stop the reaction. The plate was

Southern blot analysis
Total plant DNA was extracted from transgenic T0 plants and untransformed tobacco plants using the DNeasy Plant Mini Kit (Qiagen,
Valencia, CA, USA). Total plant DNA was digested with HincII and
probed by the flanking sequence probe, which was obtained from
the pUC-Ct vector by digesting with BamHI and BglII to yield a 0.81-kb
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immediately read on a microtitre plate reader (BioTek Instruments,
Winooski, VT, USA) using a 450-nm filter.

Estimation of TSP
The TSP of plant crude extract was determined by the Bradford
assay. Bovine serum albumin (BSA; Sigma Chemical, St. Louis, MO,
USA) was used as a standard in concentrations ranging from 0.05
to 0.5 mg/mL. Aliquots of 10 µL of diluted plant extract and each
standard were added in duplicate to wells of a 96-well microtitre
plate (Cellstar, Greiner, Nurtingen, Germany). Bradford reagent
(Bio-Rad Protein Assay, Bio-Rad) was diluted 1 : 4 with distilled
water, filtered, and 200 µL was added to each well and assayed as
described previously (Kumar and Daniell, 2004; Daniell et al., 2005b).
The absorbance was read at 595 nm.

Field production of biomass expressing IFN-α2b
IFN seeds in cultivar Nicotiana tabacum cv. ‘Petit Havana’ were
initially propagated in the glasshouse using standard tobacco
production practices for clipping, fertilizer and pesticide application
suitable for field transplantation 30 days after seeding. The field was
prepared prior to transplantation by the application of 138 kg/acre
of ammonium nitrate using a Drop Spreader™ (Gandy Company,
Owatonna, MN, USA), which was incorporated into the first 13 cm
of soil using a Soil Finisher™ (John Deere, Moline, IL, USA). In August,
seedlings were transplanted using a mechanical transplanter on nonraised beds in 40-cm rows with 30-cm plant spacings. The mean
height of the transplanted seedlings was 15 cm, with an average of
five leaves each, and planted 10 cm deep. Approximately 0.26 acre
containing 7369 plants was seeded. At the time of transplantation, the
field was prepared by applying insecticides [456 g/acre of Orthene
(Monsanto, St. Louis, MO, USA) and 43 g/acre of Admire (Bayer
CropScience, Research Triangle Park, NC, USA)] and herbicides
[231 g/acre of Spartan (Chemical Products Technologies, Cartersville,
GA, USA) and 922 g/acre of Command (FMC, Philadelphia, PA,
USA)]. Crop maintenance required application of the fungicides
Quadris (228 g/acre; Syngenta Crop Protection, Greensboro, NC, USA)
and Acrobat MZ (48 g/acre; BASF, Research Triangle Park, NC, USA)
every 20–30 days to control blue mould infestation, and a single
application of Orthene (456 g/acre) to control aphid infestation.

IFN preparation
Crude extracts of transgenic and wild-type plants were generated
using PEB as described above. Histidine-tagged transgenic cpIFNα2b was purified under native conditions by passing crude extracts
over HIS-Select spin columns (Sigma), according to the manufacturer’s
protocol. Flow-through, wash and eluate fractions were collected
separately for analysis. PEG-Intron™ was used as the positive
control for IFN-α2b activity. We routinely obtained greater than
85% purity of cpIFN-α2b (data not shown).

VSV cytopathic effect (CPE) assay
The Indiana strain of VSV was propagated in BHK cells (initial stocks
were a kind gift from Dr Glen Barber, University of Miami, Miami,
FL, USA). The virus was titrated by plaque formation on BHK cells.
All viral dilutions were made in cell culture medium.
BHK cells were seeded in a 96-well plate 1 day prior to infection at
a concentration of 1 × 105 cells/mL. Cells were treated for 6 h prior
to infection with either crude extract or purified protein (25 µL),
and then infected with 3000 plaque-forming units (PFUs) of VSV
(25 µL); control wells were treated with either VSV alone or medium
alone. The assay was stopped 24 h later. The medium from each well
was aspirated, and the cells were fixed and stained by the addition
of 100 µL of 0.5% (w/v in 70% methanol) crystal violet solution. After
1 min, the crystal violet solution was decanted and the wells were
gently rinsed with water. After drying, the wells were examined
under an inverted light microscope (Leica Microsystems, Wetzlar,
Germany) and photographs were taken with a digital camera
(Olympus America, Melville, NY, USA). The emission spectra of
the crystal violet-stained wells were determined in a microplate reader
at 570 nm.

Titrating IFN
The biological activity of the various preparations of IFN was calculated on the basis of that of PEG-Intron™ standards and expressed
in international units (IUs). The mock controls (no IFN, no VSV) were
assigned protection values of 0% and 100%, respectively. A formula
was generated that correlated the optical density (OD) readings at
570 nm with the percentage protection of the mocks. Then, using
the calculated biological activity of PEG-Intron™ (7 × 107 IU/mg), a
second formula correlating the percentage protection with the
standardized IU of PEG-Intron™ was generated, and used to calculate the biological activity of all experimental samples.

In vitro assays to study the functionality of IFN
HIV-1 inhibition assay
Cells
Baby hamster kidney (BHK) and YAC-1 cells were obtained from
ATCC. H9, PM1 and TZM-BL cells were obtained from the National
Institutes of Health (NIH) AIDS Research and Reference Reagent
Program (Germantown, MD, USA). BHK and TZM-BL cells were
cultured in high-glucose Dulbecco’s modified Eagle’s medium
(DMEM) supplemented with 10% heat-inactivated fetal bovine
serum (FBS). H9 cells were cultured in RPMI 1640 supplemented
with 10% FBS and 100 mM N-2-hydroxyethylpiperazine-N′-2ethanesulphonic acid (HEPES). PM1 cells were maintained at a
density of (4–8) × 105 cells/mL in RPMI 1640 supplemented with
20% FBS and 100 mM HEPES. YAC-1 cells were cultured in RPMI 1640
supplemented with 10% FBS, 2 mM L-glutamine, 10 mM HEPES, 1 mM
sodium pyruvate, 4.5 g/L glucose and 1.5 g/L sodium bicarbonate.

The HIV-1 laboratory strains BaL (R5) and IIIB (X4) were obtained
from the National Institutes of Health AIDS Research and Reference
Reagent Program. HIV-1 BaL was propagated in PM1 cells over
16 days. Supernatants containing virus were collected every other
day, starting 5 days after infection, passed through a 0.45-µm pore
size filter and stored in aliquots at –80 °C. HIV-1 IIIB was similarly
propagated using H9 cells. Virus was quantified by ELISA for p24gag
(Perkin-Elmer, Boston, MA, USA).
The protocol for this assay has been described elsewhere (Venkataraman et al., 2005). TZM-BL cells, also known as JC53-BL cells (Wei
et al., 2002), which contain a luciferase expression cassette driven by
the HIV LTR, were seeded in 96-well dishes (4000 cells/well). After
24 h, the cells were treated in triplicate with 50 µL of culture medium
containing various preparations of IFN-α2b or vehicle control (PBS).
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Culture medium or virus diluted in culture medium (2 ng/mL p24 for
BaL and 5 ng/mL p24 for IIIB) in 50 µL was immediately added
to each well and allowed to incubate at 37 °C in 5% CO2 for 24 h.
Luciferase activity was subsequently measured with Bright-Glo
reagents (Promega, Madison, WI, USA), according to the manufacturer’s instructions, using an LMax luminometer (Molecular
Devices, Sunnyvale, CA, USA). The cytotoxicity and the metabolic
activity of the cells were verified by a tetrazolium-based (MTT)
assay according to the manufacturer’s instructions (R&D Systems,
Minneapolis, MN, USA).

In vivo assays to study the functionality of IFN
Mice
Five-week-old C57BL/6 mice were purchased from Charles River
Laboratories (Wilmington, MA, USA). Groups of mice were treated
with PBS (three mice), PEG-Intron™ (five mice) or cpIFN-α2b (five mice)
purified from transgenic tobacco leaves. Mice were treated with
20 000 IU of cpIFN-α2b diluted in 100 µL of PBS. The biological
activity was based on the performance of purified protein in the VSV
CPE assay. The doses were administered daily for three consecutive
days via intraperitoneal injection using a tuberculin syringe fitted
with a 27-gauge needle. Mice were sacrificed 48 h after the final
dose by carbon dioxide inhalation.

following tagged secondary antibodies: rabbit anti-mouse/Alexa
488 or goat anti-rat Alexa 555. The sections were incubated with
secondary antibody for 2 h at room temperature in the dark. The
slides were washed three times; if double staining was required, the
sequence of primary antibody staining, wash, secondary antibody
staining and wash was repeated. At the end of the staining procedure, the slides were fixed by adding 50 µL of VectaShield Mounting
Medium with 4′,6-diamidino-2-phenylindole (DAPI) (Vector
Laboratories, Burlingame, CA, USA). Coverslips were set and the
slides were analysed on a Leica DM4000B fluorescent microscope
(Leica Microsystems). For each filter cube used, samples were acquired
at the same exposures to equilibrate light input. Then, using softwarespecific tools, the splenic tissue was isolated and the MFI of antibody staining was tabulated to account for both positively and
negatively stained regions alike (Adobe Systems, San Jose, CA, USA).

Ex vivo preparation of splenocytes
Spleen tissue in culture medium was dissociated using the plunger of
a 10-mL syringe over a 70-µm cell strainer (BD Biosciences). The cells
were washed once with PBS containing 2% FBS and pelleted by centrifugation at 150 × g for 10 min. The supernatant was aspirated
and the cells were resuspended in culture medium at a concentration
of 108 cells/mL.

Immunophenotyping
Reagents
All antibodies used for flow cytometry and primary antibodies for
immunohistochemistry were obtained from BD Biosciences (San Jose,
CA, USA); conjugated antibodies for immunohistochemistry were
obtained from Molecular Probes (Eugene, OR, USA).

Splenocytes were analysed for cell surface expression of the
following markers: mouse anti-H-2Kb (clone AF6-88.5) conjugated
to fluorescein isothiocyanate (FITC), rat anti-CD49b (clone DX5)
conjugated to phycoerythrin (PE) or mouse anti-NK1.1 (clone PK136)
conjugated to allophycocyanin (APC). Samples were analysed on a
FACSAria (BD Biosciences).

Collection of tissue samples
On sacrifice, mice were placed supine and the abdomen was opened
along the ventral midline. A 23-gauge butterfly needle was placed
in the right ventricle and sterile PBS was injected into the mouse for
5 min. One-half of the spleen was excised and immediately placed in
cold culture medium (RPMI 1640 supplemented with 10% FBS). A
solution of 4% paraformaldehyde (PFA) was then injected into the
mouse via the right ventricle for 15 min. The remaining portion of the
spleen was then excised and placed sequentially in 4% PFA, 10%
sucrose, 20% sucrose and 30% sucrose, each for a period of 18–
24 h. Samples were placed in Tissue Freezing Medium (Triangle Biomedical Sciences, Durham, NC, USA) and then flash frozen in 2methylbutane (Sigma) over liquid nitrogen as fixed tissue specimens.

Immunohistochemistry
Sections of fixed frozen tissue (10 µm) were taken on a cryostat
slicer (Microm HM505E; Mikron Instruments, San Markos, CA, USA)
at –20 °C. The sections were mounted on Superfrost/Plus microscope slides (Fisher Scientific, Fair Lawn, NJ, USA). The slides were
washed three times with PBS, and then blocked with PBS containing
10% BSA and 0.3% Triton X-100 for 1 h at room temperature. The
sections were stained with one of the following primary antibodies
(all antibodies were diluted 1 : 250 in PBS containing 1% BSA and
0.3% Triton X-100): mouse anti-H-2Kb (clone AF6-88.5), rat antiCD49b (clone DX5) or mouse anti-NK1.1 (clone PK136). The sections
were incubated with primary antibody overnight at 4 °C. The slides
were washed three times and then incubated with either of the
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